434 related articles for article (PubMed ID: 29738880)
1. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
[TBL] [Abstract][Full Text] [Related]
3. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Lee VM; Giasson BI; Trojanowski JQ
Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
[TBL] [Abstract][Full Text] [Related]
4. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.
Goedert M; Masuda-Suzukake M; Falcon B
Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420
[TBL] [Abstract][Full Text] [Related]
5. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
6. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
7. Distinct α-synuclein strains differentially promote tau inclusions in neurons.
Guo JL; Covell DJ; Daniels JP; Iba M; Stieber A; Zhang B; Riddle DM; Kwong LK; Xu Y; Trojanowski JQ; Lee VM
Cell; 2013 Jul; 154(1):103-17. PubMed ID: 23827677
[TBL] [Abstract][Full Text] [Related]
8. Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core.
Vacchi E; Kaelin-Lang A; Melli G
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708732
[TBL] [Abstract][Full Text] [Related]
9. A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.
Ciaccioli G; Martins A; Rodrigues C; Vieira H; Calado P
PLoS One; 2013; 8(2):e55848. PubMed ID: 23393603
[TBL] [Abstract][Full Text] [Related]
10. Interface between tauopathies and synucleinopathies: a tale of two proteins.
Galpern WR; Lang AE
Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
[TBL] [Abstract][Full Text] [Related]
11. Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.
Yeboah F; Kim TE; Bill A; Dettmer U
Neurobiol Dis; 2019 Dec; 132():104543. PubMed ID: 31351173
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.
Lu J; Zhang S; Ma X; Jia C; Liu Z; Huang C; Liu C; Li D
J Biol Chem; 2020 May; 295(21):7470-7480. PubMed ID: 32291284
[TBL] [Abstract][Full Text] [Related]
13. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
14. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
[TBL] [Abstract][Full Text] [Related]
15. Interactions of pathological proteins in neurodegenerative diseases.
Spires-Jones TL; Attems J; Thal DR
Acta Neuropathol; 2017 Aug; 134(2):187-205. PubMed ID: 28401333
[TBL] [Abstract][Full Text] [Related]
16. Protein Partners of α-Synuclein in Health and Disease.
Lassen LB; Reimer L; Ferreira N; Betzer C; Jensen PH
Brain Pathol; 2016 May; 26(3):389-97. PubMed ID: 26940507
[TBL] [Abstract][Full Text] [Related]
17. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR
Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Tau and α-Synuclein Pathology in the Visual System.
Rahimi J; Milenkovic I; Kovacs GG
J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases.
Nonaka T; Masuda-Suzukake M; Hasegawa M
Neuropathology; 2018 Feb; 38(1):64-71. PubMed ID: 28948653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
